Drug Formulation and Manufacturing Contracts 2019
Ended Master IDIQ Awarded
- Federal agency
-
Office of Logisitics and Acquisition Operations
- Awardees
- 5
- Task orders
- 14
- Obligated
- $5,766,604
Vehicle facts
- Opportunity
-
- 75N98019R00005 Solicitation number
- Agency
-
- Office of Logisitics and Acquisition Operations National Institutes of Health, Department of Health and Human Services
- Combined task order value
-
- $5,766,604 Current, with exercised options
- $5,992,016 Potential, with all options
- Last date to order 100% complete
- Shared ceiling 13% used
- $45,000,250.00
IDV award and task order details come from SAM.gov/FPDS.
About this vehicle
The National Institutes of Health Office of Logistics and Acquisition Operations awarded this master IDIQ for drug formulation and manufacturing on September 27, 2019, with a shared ceiling of $45 million; ordering closed on September 27, 2024, and is no longer active.
The vehicle funds development and manufacture of dosage forms of small-molecule drug candidates for preclinical efficacy studies, Investigational New Drug enabling studies, and clinical trials across NIH institutes. Task orders executed to date show heavy emphasis on production of GMP and engineering batches of specialized capsules and injectables—including AZA-TDC, Z-Endoxifen, TAK-243, ATTM, Novobiocin, Triapine, and Ketamine formulations—paired with stability testing and shelf-life studies of finished pharmaceutical products and active pharmaceutical ingredients. Pricing is predominantly firm fixed price with one cost-plus-fixed-fee order.
Three prime contractors shared the 14 task orders awarded through April 2024. Mriglobal holds the largest combined potential value at $3.4 million across three orders, while Societal CDMO San Diego, LLC won ten orders worth $2.5 million combined, and Alchem Laboratories Corporation received one order for $180 thousand. The vehicle is unrestricted at the vehicle level; 93% of task orders carried no set-aside, with one order designated partial small business.
The National Cancer Institute drove demand with ten orders totaling $3.6 million in combined potential value, followed by the Office of Logistics and Acquisition Operations itself with three orders worth $2.3 million. The National Institute on Aging placed one order for $100 thousand. Obligated spend reached $5.8 million against $6 million combined potential value across all task orders (96% obligation rate), indicating heavy drawdown of the vehicle before ordering window closed. Task-order values ranged from $10 thousand to $2.3 million, with the Ketamine production order representing the largest single award. Ordering momentum declined sharply in 2024, with only one order placed before the vehicle's September 2024 cutoff after consistent three-order annual pace in prior years.
Description
The Drug Formulation and Manufacturing Contracts (DFMC) will allow NIH ICs to hire contractors to conduct the development and manufacture of dosage forms of small molecule drug candidates suitable for administration in preclinical efficacy studies, Investigational New Drug (IND) enabling studies, and clinical trials.
IDV awards
Latest task orders
Show all 14
Top awardees by obligations
| Rank | Awardee | Obligated | Share |
|---|---|---|---|
| 1 | Mriglobal | $3,359,377 | 58% |
| 2 | Societal Cdmo San Diego, LLC | $2,227,007 | 39% |
| 3 | Alchem Laboratories Corporation | $180,220 | 3% |
Top funding agencies by obligations
| Rank | Funding agency | Obligated | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $5,766,604 | 100% |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2025 | $124,460 |
| FY2024 | $417,942 |
| FY2023 | $1,143,528 |
| FY2022 | $1,433,881 |
| FY2021 | $1,412,451 |
| FY2020 | $1,234,343 |
Quick answers
What is the Drug Formulation and Manufacturing Contracts 2019 contract vehicle?
Drug Formulation and Manufacturing Contracts 2019 is an indefinite delivery, indefinite quantity (IDIQ) contract vehicle run by Office of Logisitics and Acquisition Operations (National Institutes of Health), awarded on September 27, 2019.
Which companies hold Drug Formulation and Manufacturing Contracts 2019?
5 companies hold Drug Formulation and Manufacturing Contracts 2019's IDV awards, one each. The latest went to Societal Cdmo San Diego, LLC on September 27, 2019. The awardees whose task orders obligated the most are Mriglobal, Societal Cdmo San Diego, LLC and Alchem Laboratories Corporation.
How much has been spent through Drug Formulation and Manufacturing Contracts 2019?
14 task orders have been placed under Drug Formulation and Manufacturing Contracts 2019, obligating $5,766,604.
What is the shared ceiling of Drug Formulation and Manufacturing Contracts 2019?
Drug Formulation and Manufacturing Contracts 2019's shared ceiling is $45,000,250; its task orders have used 13% of it.
Which agencies use Drug Formulation and Manufacturing Contracts 2019 the most?
The departments whose task orders under Drug Formulation and Manufacturing Contracts 2019 obligated the most are Department of Health and Human Services ($5,766,604).
How much was obligated through Drug Formulation and Manufacturing Contracts 2019 in fiscal year 2025?
Task orders under Drug Formulation and Manufacturing Contracts 2019 obligated $124,460 in fiscal year 2025.
On GovTribe
See this vehicle's full record
- Every IDV award and task order
- Funding by agency, awardee, NAICS and set-aside
- Teaming partners on this vehicle
- Ask GovTribe AI about this vehicle